Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19/BCMA CAR-NK Cell Injection in Refractory Pediatric Rheumatic Diseases
NCT07490041Phase 1Recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KN5601 in polyarticular juvenile idiopathic arthritis, Sjögren's syndrome, juvenile dermatomyositis (JDM) and 3 more, sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoint: Incidence of Dose-Limiting Toxicity at 28 days. Started Mar 2026; status: recruiting.
02
Drugs
KN5601
03
Conditions
polyarticular juvenile idiopathic arthritisSjögren's syndromejuvenile dermatomyositis (JDM)systemic sclerosis (SSc)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07490041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07490041.